Relative protein intake and associations with markers of physical function in those with type 2 diabetes

Nutritional Approach to Diabetic Sarcopenia: A Comprehensive Review

PURPOSE OF THE REVIEW

The aim of this review is to discuss and evaluate diabetic sarcopenia (DS) and its relationship with nutrition by discussing the mechanisms of diabetic sarcopenia in detail and comprehensively reviewing the literature.

RECENT FINDINGS

Type 2 diabetes (T2DM) affects approximately 25% of people aged 50 years and over and indicates a significant the cost of health for the elderly. Nutrition is an important part of these treatment approaches, and in this review, the literature was comprehensively reviewed, focusing on understanding the mechanisms of DS and discussing its relationship with nutrition. A comprehensive search was conducted on Web of Science, Google Scholar, Scopus, Science Direct, and PubMed from inception up to July 2024. The aim of nutritional treatment for DS is to improve muscle mass, muscle strength and physical performance while improving diabetes-related metabolic risk and glucose levels. In this context, it is important to determine energy intake in individuals with DS according to calorie intake exceeding 30 kcal/kg. For these individuals, a protein intake of at least 1-1.2 g/kg/day is recommended, with an emphasis on the number and timing of meals and a nutritional pattern rich in branched chain amino acids (BCAA). In addition, it is important to adopt a diet rich in antioxidants and to choose diet patterns that contain sufficient levels of macro and micronutrients. The Mediterranean diet model can be a good diet option for individuals with DS. Comprehensive studies in this field are needed so that clinicians can make specific dietary recommendations for DS.

The effects of dietary protein on physical performance and body composition in middle age and older people having type II diabetes mellitus: a randomized pilot study

PURPOSE

Protein supplementation has been proposed as an effective dietary strategy for maintaining or increasing skeletal muscle mass and improving physical performance in middle-aged and older adults. Diabetes mellitus exacerbates muscle mass loss, leading to many older adults with type 2 diabetes mellitus (T2DM) experiencing sarcopenia, and vice versa. Our objective was to assess the impact of increased dietary protein intake on muscle mass, strength, physical performance, and the progression of T2DM in middle-aged and older adults diagnosed with this condition.

METHODS

A 12-week randomized, controlled, parallel pilot study was conducted with 26 patients diagnosed with T2DM and had either low muscle mass, or low muscle strength or poor physical performance (age > 55 years old), aiming to investigate the effects of a protein-rich diet in sarcopenic and metabolic markers. The control group received 0.8-1.0 g/kg/day, while the intervention group received 1.2-1.5 g/kg/day of protein respectively. Body composition, muscle mass/strength and biochemical parameters were measured before and after the intervention period.

RESULTS

Different kinetics of skeletal muscle index (SMI), appendicular lean mass (ALM), hand grip strength (HGS), gait speed (GS) and standing balance (SB) (p < 0.05) were observed between two groups. Specifically, the intervention group showed a significant improvement in HGS (p < 0.001) and physical performance (timed-up-and-go, p < 0.001; GS, p = 0.011; SB, p = 0.022), while the control group had its ALM (p = 0.014), SMI (p = 0.011) and HGS (p = 0.011) significantly reduced. The kinetics of metabolic markers indices was similar for both groups.

CONCLUSION

Current recommendation for protein intake (0.8-1 g/kg/day) is certainly not enough to ameliorate the muscle mass loss in middle age and older adults' individuals with T2DM. In contrast, protein intake of 1.2-1.5 g/kg/day seems to be a more appropriate recommendation to combat upcoming sarcopenia, nonetheless the progression of T2DM was not interrupted.

Pathogenesis and comprehensive treatment strategies of sarcopenia in elderly patients with type 2 diabetes mellitus

Sarcopenia and diabetes are two age-related diseases that are common in the elderly population, and have a serious effect on their general health and quality of life. Sarcopenia refers to the progressive loss of muscle mass, strength and function, whereas diabetes is a chronic disease characterized by elevated blood sugar levels. The comorbidity of sarcopenia and diabetes is particularly concerning, as people with diabetes have a higher risk of developing sarcopenia due to the combination of insulin resistance, chronic inflammation and reduced physical activity. In contrast, sarcopenia destroyed blood sugar control and exacerbated the development of people with diabetes, leading to the occurrence of a variety of complications. Fortunately, there are a number of effective treatment strategies for sarcopenia in people with diabetes. Physical exercise and a balanced diet with enough protein and nutrients have been proved to enhance the muscular quality and strength of this population. Additionally, pharmacological therapies and lifestyle changes can optimize blood sugar control, which can prevent further muscle loss and improve overall health outcomes. This review aims to summarize the pathogenesis and comprehensive treatment strategies of sarcopenia in elderly patients with type 2 diabetes, which help healthcare professionals recognize their intimate connection and provide a new vision for the treatment of diabetes and its complications in this population. Through early identification and comprehensive treatment, it is possible to improve the muscle function and general quality of life of elderly with diabetes and sarcopenia.

Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes

Diabetes prevalence is increasing rapidly in older people, and sarcopenia is prevalent as a novel complication, particularly in patients with type 2 diabetes mellitus (T2DM). Therefore, sarcopenia prevention and treatment in these people is necessary. Diabetes accelerates sarcopenia through several mechanisms, such as hyperglycemia, chronic inflammation and oxidative stress. The effects of diet, exercise, and pharmacotherapy on sarcopenia in patients with T2DM need to be considered. In diet, low intake of energy, protein, vitamin D, and ω-3 fatty acid are associated with sarcopenia risk. In exercises, although intervention studies in people, especially older and non-obese patients with diabetes, are few, accumulating evidence shows the usefulness of exercise, particularly resistance exercise for muscle mass and strength, and aerobic exercise for physical performance in sarcopenia. In pharmacotherapy, certain classes of anti-diabetes compounds have possibility of preventing sarcopenia. However, much data on diet, exercise, and pharmacotherapy were obtained in obese and non-elderly patients with T2DM, demanding actual clinical data on non-obese and older patients with diabetes.

Protein and Leucine Intake at Main Meals in Elderly People with Type 2 Diabetes

Background: The recommended protein intake for the elderly is 25–30 g at main meals, with at least 2500–2800 mg of leucine at each meal. There is still little evidence regarding the amount and distribution of protein and leucine intake with meals in the elderly with type 2 diabetes (T2D). In this cross-sectional study, we evaluated protein and leucine intake at each meal in elderly patients with T2D. Methods: A total of 138 patients (91 men and 47 women) with T2D, aged 65 years or older, were included. Participants performed three 24-h dietary recalls for the evaluation of their dietary habits and protein and leucine intake at meals. Results: The average protein intake was 0.9 ± 0.2 g/kg body weight/day, and only 23% of patients complied with the recommendations. The average protein intake was 6.9 g at breakfast, 29 g at lunch, and 21 g at dinner. None of the patients reached the recommended protein intake at breakfast; 59% of patients complied with the recommendations at lunch; and 32% at dinner. The average leucine intake was 579 mg at breakfast, 2195 g at lunch, and 1583 mg at dinner. The recommended leucine intake was not reached by any patient at breakfast, by 29% of patients at lunch, and by 13% at dinner. Conclusions: Our data show that, in elderly patients with T2D, the average protein intake is low, particularly at breakfast and dinner, and that leucine intake is remarkably lower than the recommended levels. These data raise the need to implement nutritional strategies capable of increasing protein and leucine intake in the elderly with T2D.